ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Nephrology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,594Medicare Part D Prescriptions Filled, Including Refills

Rank: 14 out of 226

$581K Total Retail Price of All Prescriptions

Rank: 47 out of 226

400 Patients Receiving at Least One Drug in Part D
67%Patients 65 Years and Older
89% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Georgia
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 400 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

9% of this provider’s 400 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

2% of this provider’s 6,036 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$68 was the average price of a prescription from this provider, compared to $106 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 13.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Georgia
AMLODIPINE BESYLATE 446 299 1 1
LISINOPRIL 312 224 2 3
SIMVASTATIN 302 197 3 10
FUROSEMIDE 288 238 4 2
RANITIDINE HCL 279 213 5 47
CALCITRIOL 265 198 6 8
CITALOPRAM HBR 195 132 7 52
HYDROCODONE-ACETAMINOPHEN 193 129 S3 8 17
DONEPEZIL HCL 170 164 9 79
CALCIUM ACETATE 148 82 10 14
CARVEDILOL 146 86 11 7
SENSIPAR 140 58 12 6
BENAZEPRIL HCL 140 44 12 49
NOVOLIN R 127 100 14 147
METOPROLOL TARTRATE 122 82 15 9
LEVOTHYROXINE SODIUM 119 105 16 18
RENVELA 116 37 17 4
GABAPENTIN 115 85 18 21
OMEPRAZOLE 109 86 19 16
ALLOPURINOL 101 73 20 11
HYDROCHLOROTHIAZIDE 100 75 21 20
LANTUS 98 87 22 53
NOVOLIN 70-30 95 42 23 137
RISPERIDONE 91 63 24 140
NAMENDA 88 88 25 127
PHENYTOIN SODIUM EXTENDED 84 73 26 166
LOSARTAN POTASSIUM 76 48 27 13
QUETIAPINE FUMARATE 73 49 28 136
ZOLPIDEM TARTRATE 73 67 28 29
CARBIDOPA-LEVODOPA 71 71 30 176
CLONIDINE HCL 71 48 30 12
DOXAZOSIN MESYLATE 67 35 32 19
TRAZODONE HCL 65 41 33 83
BACLOFEN 65 31 33 186
NIFEDIPINE ER 63 21 35 15
FAMOTIDINE 63 52 35 35
MEGESTROL ACETATE 61 61 R 37 71
CLOPIDOGREL 61 39 37 44
POLYETHYLENE GLYCOL 3350 60 46 39 122
WARFARIN SODIUM 58 39 40 37
HYDRALAZINE HCL 58 44 40 5
KLOR-CON M20 55 32 42 41
ATENOLOL 55 46 42 32
SPIRONOLACTONE 54 35 44 33
DIVALPROEX SODIUM 54 42 44 201
KLOR-CON M10 53 43 46 144
MIRTAZAPINE 52 41 47 102
TRAMADOL HCL 51 26 48 28
FENTANYL 50 50 S2 49 209
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 20, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.